Chief Executive Officer at Nanotein Technologies, Inc. - Berkeley, California, United States
Using our novel platform technology, we at Nanotein, help overcome the CAR-T industry challenges by: (1) accelerating CAR-T expansion, (2) enhancing expansion to grow more cells per treatment, and (3) shifting the growth profile of CAR-T cultures to favor the expansion of the most long-lived and clinically effective CAR-T cell sub-populations.The uniquely tunable and flexible nature of our platform technology also allows us to easily modify our product. With the ability to make these simple changes we can grow CAR-T and T-cell cultures with new cell population profiles and growth curves.